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THE FUTURE OF BIOTECHNOLOGY: ACCELERATING 
GENE-EDITING ADVANCMENETS THROUGH NON-
EXCLUSIVE LICENSES AND OPEN-SOURCE ACCESS OF 
CRISPR-CAS9. 
 
By Emily N. Rissberger1 
 
From the immune system of bacteria comes a promising new gene-
editing technology, CRISPR-Cas9. Discovered in 2012, CRISPR-Cas9 
has already been named one of the fastest, easiest, and cheapest gene-
editing technologies. With this reputation, CRISPR-Cas9 shows 
promise in the research and treatments of a wide array of diseases. 
Cancer, blood disorders, blindness, AIDS, Cystic Fibrosis, Muscular 
Dystrophy, Huntington’s disease, and even COVID-19 to name a few. 
This relatively new technology has brought hope to researchers, 
doctors, and patients alike. However, current biotechnology licensing 
practices could hinder CRISPR-Cas9’s groundbreaking potential.  
This article examines common biotechnology licensing practices, 
specifically the practices of two of the largest CRISPR-Cas9 patent 
holders, The University of Berkeley and The Broad Institute of MIT 
and Harvard. After each institution’s respective CRISPR-Cas9 
discovery the two battled it out to determine which institution 
discovered CRIPR-Cas9 first and whether patent infringement existed. 
Eventually, both institutions were granted their desired patents and 
quickly ensured the future of their technologies, created independent 
companies to control the licensing of CRISPR-Cas9 patents. This 
article refers to such companies as “surrogate companies” and 
explains the function of these entities as the gatekeeper of valuable 
patent rights through overinclusive exclusive licenses.  
This article offers solutions to existing exclusive licenses without 
losing sight of the important relationship between research institutions 
and surrogate companies. Providing limited field of use licenses, 
rather than overinclusive exclusive licenses, of CRISPR-Cas9 patented 
technology will ensure a wider range of the human genome be 
discovered. Limited licenses allow companies to focus on specific 
goals, reducing the possibility of a gene therapy being overlooked and 
underdeveloped. This article goes further, suggesting the 
biotechnology industry adopt an open-source access model like the one 
used in the software industry. Such a model could prove beneficial for  
      
1 Tech Edge JD Candidate, Santa Clara University School of Law, 2022. The 
author thanks her friends and family for their unwavering support and 
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companies looking to expand product offerings while still maintaining 
profits. Historically low-profit diseases like tropical diseases could 
become more desirable to companies based on collaboration and 
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The ability to modify genes “easily and efficiently . . .  holds 
immense promise to transform basic science, biotechnology, and 
medicine.”2 CRISPR-Cas9 is one of the promising technologies in 
gene editing. With promising results in sickle cell disease trials and 
opportunities to treat genetic diseases such as cystic fibrosis and 
muscular dystrophy, CRISPR-Cas9 is the future of medicine.3 
Unfortunately, the potential of this revolutionary technology is 
dwindling, with CRISPR-Cas9 patent owners putting profits over 
accessibility and broad application.  
The biotechnology industry provides hope for the future of 
disease management and treatments. However, the industry is 
currently riddled with patent thickets (multiple over-inclusive patents 
covering the same area of technology), over-inclusive licenses, and a 
profit over progress mindset that currently inhibits the industry’s 
revolutionary potential.  As a relatively new industry, biotechnology 
can take inspiration from the software industry’s open-source model, 
providing public access to research and encouraging collaboration to 
create the future of biotechnology.  
I. AN INTRODUCTION TO GENE EDITING 
Genome-editing (gene-editing) is a group of technologies that 
allow genetic material to be altered.4 Editing occurs at a particular 
location in the genome that allows scientists to change an organism's 
DNA.5 Gene-editing has been used to genetically modify crops to 
improve yields, prevent disease, and survive droughts.6 Crops that 
have undergone such editing are genetically modified organisms or 
GMOs.7 Gene-editing is also used to research and treat diseases 
      
1 Patrick D. Hsu, Eric S. Lander, Feng Zhang, Development and Applications 
of CRISPR-Cas9 for Genome Engineering, CELL, 1262, 1263 (June 5, 2014). 
3 Emily Mullin, Fresh Off Her Nobel Prize Win, Jennifer Doudna Predicts 
What’s Next for CRISPR, Future Human (Oct. 12, 2020), 
https://futurehuman.medium.com/fresh-off-her-nobel-prize-win-jennifer-
doudna-predicts-whats-next-for-crispr-1fea0225c41d. 
4 What are genome editing and CRISPR-Cas9?, U.S. NATIONAL LIBRARY OF 




6 What is genome editing?, yourgenome (Aug. 23, 2017), 
https://www.yourgenome.org/facts/what-is-genome-editing. 
7 What is a GMO?, yourgenome (Feb. 17, 2017), 
https://www.yourgenome.org/facts/what-is-a-gmo. 




currently “being explored in research on a wide variety of diseases, 
including single-gene disorders such as cystic fibrosis, hemophilia, and 
sickle cell disease . . . and more complex diseases such as cancer and 
AIDS.”8 
A. How Gene-Editing Works 
On a basic level, gene-editing is the process of slicing and 
dicing genetic material to change the structure of targeted DNA.9 More 
specifically, an enzyme referred to as an “engineered nuclease” cuts a 
genome in a specific location.10 After being cut, the cell naturally 
repairs itself.11 This repair process is where the “editing” occurs.12 
During the repair process, some of the DNA may be lost or added 
around the site of the cut.13 These deletions or additions affect the 
function of the DNA.14 To remove DNA, an engineered nuclease cuts 
either side of the section to be removed.15 To repair this cut, the DNA 
recognizes the damage done and joins the ends of the two cuts 
together.16 To insert a new section of DNA, an engineered nuclease 
cuts a specific location and introduces a modified piece of the 
previously cut DNA into the location. 17 The cell uses this modified 
piece to fill in the cut section.18 
II. CRISPER-CAS9: A REVOLUTIONARY GENE EDITING 
TECHNOLOGY 
There are several kinds of engineered nucleases used in gene-
editing. One of the most commonly used engineered nucleus is 
CRISPR-Cas9, originally discovered in bacteria that use CRISPR-
Cas9 to destroy invading viruses.19 CRISPR stands for “clustered 
      
8 What are genome editing and CRISPR-Cas9?, supra note 3.  
9 What is genome editing?, supra note 5.   




14 What is genome editing?, supra note 5. 
15 Id. 
16 Id. 
17 What is genome editing?, supra note 5. 
18 Id. 
19 Thomas Gaj, Shannon J. Sirk, Sai-Ian Shui, & Jia Liu, Genome-Editing 
Technologies: Principles and Applications, Cold Spring Hard Perspect Biol, 
(Dec. 2016), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131771/. See 
also, University of Zurich. New Bacterial Defense Mechanism of the CRISPR-
Cas System Uncovered, ScienceDaily (July 18, 2017), 
https://www.sciencedaily.com/releases/2017/07/170718113722.htm. 





regularly interspaced short palindromic repeats,”20 and Cas9 represents 
CRISPR-associated protein 9.21 CRISPR can be accompanied by other 
Cas proteins such as Cas12, Cas14, CasX, and CasY.22 However, this 
article’s main focus is on CRISPR-Cas9 and will stick to referring only 
to the Cas9 protein system. To utilize CRISPR-Cas9, researchers 
create a guide sequence of RNA which is attached to the DNA 
sequence being edited.23 The guide RNA shows the Cas9 protein where 
to cut the DNA, and the Cas9 protein proceeds with the cut. 24 Once 
cut, researchers manipulate the cell’s DNA repair mechanism to either 
add or delete genetic material.25 Researchers can also change DNA by 
“replacing an existing segment with a customized DNA sequence.”26 
A. CRISPR-Cas9 in Use 
CRISPR-Cas9 can be used either by editing cells that have 
been removed from the body or injecting the gene-editing system 
directly into the body.27 The latter process has been used in a clinical 
trial to treat Leber’s Congenital Amaurosis (LCA10), a rare cellular 
mutation that disables light-sensing cells in the retina.28 LCA10 is also 
      
20 What are genome editing and CRISPR-Cas9?, supra note 3. 
21 Heidi Ledford & Ewen Callaway, Pioneers of Revolutionary CRISPR Gene 
Editing Win Chemistry Nobel, Nature (Oct. 7, 2020), 
https://www.nature.com/articles/d41586-020-02765-9. 
22 Fiona Mischel, Who Owns CRISPR in 2021? It’s Even More Complicated 





26 What are genome editing and CRISPR-Cas9?, supra note 3.  
27 See Rob Stein, In A 1st, Scientists Use Revolutionary Gene-Editing Tool To 
Edit Inside A Patient, NPR (Mar. 4, 2020), 
https://www.npr.org/sections/health-shots/2020/03/04/811461486/in-a-1st-
scientists-use-revolutionary-gene-editing-tool-to-edit-inside-a-patient. See 
also Rob Stein, He Inherited A Devastating Disease. A CRISPR Gene-Editing 




28 Rob Stein, In A 1st, Scientists Use Revolutionary Gene-Editing Tool To Edit 
Inside A Patient, NPR (Mar. 4, 2020), https://www.npr.org/sections/health-
shots/2020/03/04/811461486/in-a-1st-scientists-use-revolutionary-gene-
editing-tool-to-edit-inside-a-patient. 




one of the most common causes of childhood blindness.29 Microscopic 
droplets carrying the CRISPR-Cas9 gene-editing system were injected 
into the patient’s eye in hopes of repairing the gene mutation.30 This 
procedure demonstrates CRISPR-Cas9’s ability to “open entire[ly] 
new areas of medicine and lead to a whole new class of therapies for 
diseases that are not treatable any other way.”31 
Currently, “one of the biggest challenges with applying 
CRISPR clinically so far, [] is being able to deliver it systemically and 
get it to the right place.”32 In June of 2021, early data indicated direct 
injection of CRISPR-Cas9 into a patient’s bloodstream was a 
success.33 CRISPR-Cas9 was injected directly into the bloodstream of 
patients with transthyretin amyloidosis, a rare inherited disease that 
produces misshapen proteins that attack important tissues and nerves.34 
Amyloidosis deteriorates the body, eventually leading to death.35 The 
amyloidosis treatment is the first instance of CRISPR-Cas9 being 
injected directly into a patient’s bloodstream.36 The injection of 
CRISPR-Cas9 into the bloodstream significantly reduced the levels of 
destructive proteins in patients.37 Injecting directly into a patient 
bloodstream could help overcome CRISPR-Cas9’s delivery 
challenges, opening the door to further treatment of diseases that affect 
tissue not located near possible injection sites.38  
B. The Institutions Behind Discovering CRISPR-Cas9 
The CRISPR-Cas9 engineered nuclease is “faster, cheaper, 
more accurate, and more efficient than other existing genome editing 
methods.”39 CRISPR-Cas9 has the potential to transform the way 
scientists study disease and the human genome. This makes it a highly 
      
29 Bill Holton, Vision Tech: Several Gene Therapies for Blindness Reach 
Clinical Trials, American Foundation for the Blind, (Nov. 2019), 
https://www.afb.org/aw/20/11/16815. 
30 Id.  
31 Id. (alteration in original). 
32 Rob Stein, He Inherited A Devastating Disease. A CRISPR Gene-Editing 










39 What are genome editing and CRISPR-Cas9?, supra note 3. 





desirable technology that has been mired with intellectual property 
(“IP”) rights disputes.40 UC Berkeley and the Broad Institute of MIT 
and Harvard (hereinafter “Broad” or “Broad Institute”) are the main 
contenders in the fight for CRISPR-Cas9 IP rights.41 Both parties claim 
the IP rights to CRISPR-Cas9 technology.  
In 2012, Berkeley Professor of Chemistry, Jennifer Doudna, 
and her team developed the CRISPR-Cas9 technology,42 applying to 
patent their discovery with the USPTO in May of the same year.43 At 
the same time, a team at the Broad Institute was researching human 
gene-editing CRISPR technology.44 The Broad Institute team’s first 
application of CRISPR-Cas9 in eukaryotic cells used a guide that 
combined two RNA molecules, while the UC Berkeley team’s 
CRISPR relied on a single RNA rather than two to accomplish the 
same result.45 This single-molecule guide RNA is now the standard 
tool in the field.46  
The Broad Institute team filed a patent for its CRISPR 
technology in December of 2012.47 Although the UC Berkeley team 
had applied seven months prior, the Broad Institute team was awarded 
its CRISPR patent48 first because the Broad Institute paid to expedite 
their application.49 As of 2013, the USPTO has operated under a first-
to-file system.50 This system would have alleviated the resulting legal 
battle between UC Berkeley and the Broad Institute.51  
Consequently, in 2016 the UC Berkeley team requested that 
the U.S. Patent Trial and Appeal Board (PTAB) begin an interference 
proceeding to determine which team was entitled to CRISPR-Cas9 
rights.52 These proceedings found no interference between the 
      
40 Mischel, supra note 21. 
41 Id. 
42 Mark Summerfield, Who Will Get the CRISPR Patent?, Patentology (Jan. 
17, 2016), https://blog.patentology.com.au/2016/01/who-will-get-crispr-
patent.html. 
43 U.S. Patent No. 10,266,850 (issued Apr. 23, 2019). 
44 Jon Cohen, The Latest Round in the CRISPR Patent Battle has an Apparent 
Victor, but the Fight Continues, ScienceMag (Sept. 11, 2020), 
https://www.sciencemag.org/news/2020/09/latest-round-crispr-patent-battle-
has-apparent-victor-fight-continues. 
45 Id.  
46 Id. 
47 Summerfield, supra note 41. 
48 U.S. Patent No. 8,697,359 (issued Apr. 15, 2014). 
49 Summerfield, supra note 41. 
50 Id. 
51 Mischel, supra note 21. 
52 Summerfield, supra note 41. 




CRISPR-Cas9 patents for gene and animal cells held by the Broad 
Institute and the patent application for gene editing in all environments 
filed by UC Berkeley.53 In 2018, a Federal Circuit affirmed the U.S. 
Patent Board’s finding54 allowing the Broad Institute to “maintain its 
extensive CRISPR patent portfolio.”55  This decision did not 
interfere with UC Berkeley’s patent application which was 
eventually granted. 56 
Recently in September of 2020, the PTAB ruled that “the 
Broad Institute has ‘priority’ in its already granted patents for uses of 
the original CRISPR system in eukaryotic cells.”57 Such a patent 
covers potentially lucrative applications in humans and lab-grown 
human cells.58 However, UC Berkeley is still hopeful that the ruling 
will lead to the “PTAB [ ] recogniz[ing] that the [UC Berkeley] team 
was first to invent the CRISPR-Cas9 technology in eukaryotic cells.”59 
The European Patent Office (“EPO”) has added complexity to 
the already complex CRISPR-Cas9 patent battle. In 2012, the EPO 
favored UC Berkeley, granting the university its CRISPR-Cas9 patents 
before Broad due to a technical issue on Broad’s application. 60 
However, more recently in 2021, the EPO has revoked two of UC 
Berkley’s CRISPR-Cas9 patents based on an invalid priority claim.61 
Although this article focuses on the CRISPR-Cas9 battle in the United 
States, these EPO decisions provide insight into the ever-changing 
gene-editing patent landscape. This article focuses on United States 
      
53 Public Affairs, UC Files Appeal to Revive CRISPR Patent Interference, 
Berkeley News (July 26, 2017), https://news.berkeley.edu/2017/07/26/uc-
files-appeal-to-revive-crispr-patent-interference/. 
54 Regents of Univ. of California v. Broad Inst., Inc., 903 F.3d 1286, 1296-97 
(Fed. Cir. 2018). 
55 Kevin Noonan, Federal Circuit Affirms PTAB in Appeal of CRISPR 




57 Cohen, supra note 43.  
58 Id.  
59 Id.  
60 Vincent M. Grandpré & Felicia Lozon, Making Sense of the Battle for the 
CRISPR-Cas9 Patent Rights, Osler (Mar. 15, 2021), 
https://www.osler.com/en/resources/critical-situations/2021/making-sense-
of-the-battle-for-the-crispr-cas9-patent-rights. 
61 Chrisitane G. Espino & Fangli Chen, UC Berkeley CRISPR Patent Revoked 
in Europe Due To Invalid Priority Claim, 11 Nat’l L. Rev. (May 24, 2021), 
https://www.natlawreview.com/article/uc-berkeley-crispr-patent-revoked-
europe-due-to-invalid-priority-claim. 





patent law in analyzing the current CRISPR-Cas9 landscape. However, 
the above information on the EPO shows the complexity of this 
revolutionary technology and the potential ownership issues that can 
arise when research is conducted globally. 
C. The Extensive CRISPR-Cas9 Patent Portfolios of UC 
Berkeley and Broad Institute of MIT and Harvard 
Despite the ongoing patent dispute between UC Berkeley and 
Broad Institute, both institutions have managed to accumulate large 
CRISPR-Cas9 patent portfolios. With both UC Berkeley and Broad 
Institute holding CRISPR patents “a third party wishing to utilize the 
technology in eukaryotic cells (encompassing everything from yeast 
to man) would need a license from both the University [of California 
Berkeley] and Broad [Institute].”62 Multiple companies have been 
founded on UC Berkeley and Broad’s initial CRISPR IP rights, 
specifically Caribou Biosciences (UC Berkeley) and Editas Medicine 
(Broad).63 These “for-profit surrogate companies”64 act as the patent 
owner, functioning as the “gatekeepers” to the CRISPR-Cas9 gene-
editing industry.65 The surrogate model allows universities and 
institutions to maximize profits while minimizing licensing risks.66 
With a surrogate company dealing with licensing, universities and 
institutions are free to focus on research and development to expand 
their patentable technologies further.67 
Currently, UC Berkeley holds the United States’ largest 
CRISPR-Cas9 patent portfolio,68 gaining 18 CRISPR-Cas9 related 
patents in 2019.69 As of May 2021, UC Berkeley owns 44 CRISPR-
      
62 Noonan, supra note 54.  
63 Mischel, supra note 21. 
64 Lisa M. Krieger, How UC-Berkeley’s CRISPR License Could Limit 
Innovation, The Mercury News (Feb. 16, 2017), 
https://www.mercurynews.com/2017/02/16/how-uc-berkeleys-crispr-
license-could-limit-innovation/. 
65 Jorge L. Contreras & Jacob S. Sherkow, CRISPR, Surrogate Licensing, and 
Scientific Discovery, 355 SCIENCE 698, 698 (2017).  
66 Id. 
67 Id. 
68 Public Affairs, UC Now Holds Largest CRISPR-Cas9 Patent Portfolio, 
Berkeley News (Oct. 1, 2019), https://news.berkeley.edu/2019/10/01/uc-
now-holds-largest-crispr-cas9-patent-portfolio/. 
69 Robert Sanders, UC Rings Out 2019 with its 20th CRISPR Patent, Berkeley 
News (Dec 31, 2019), https://news.berkeley.edu/2019/12/31/uc-rings-out-
2019-with-its-20th-crispr-patent/. 




based patents in the United States.70 This collection of patents can 
be used by nonprofits and academic institutions for non-commercial 
research and educational purposes as part of UC Berkeley’s open-
licensing policy.71 Commercial use of these patents is exclusively 
licensed to Caribou Biosciences (“Caribou”).72 Caribou sublicenses 
UC Berkeley’s CRISPR patents to “strategic partners who are 
“recognized leaders in many market sectors.”73 One such partner is 
Intellia Therapeutics Inc., another UC Berkeley surrogate company 
created for CRISPR-Cas9 application in human therapeutic.74  
Similar to UC Berkeley, Broad Institute also requires an 
exclusive license to use its CRISPR IP for human therapeutic 
research and development.75 Broad Institute only waives the need for 
a written license for institutions looking to use its CRISPR-Cas9 IP 
for academic and non-profit research.76 Under its “inclusive 
innovation” model, an alternative term for the exclusive license 
model, Broad Institute licenses its CRISPR-Cas9 technology to a 
primary licensee.77 After a specified time, non-competitors of the 
primary licensee may apply for a CRISPR-Cas9 license by 
presenting Broad Institute with a development plan.78 This 
development plan explains how the company will use Broad 
Institute’s CRISPR IP.79 
The primary licensee has access to this development plan to 
ensure the plan does not infringe on the primary licensee’s exclusive 
      
70 Robert Sanders, UC Berkeley Will Auction NFTs of Nobel Prize-Winning 
Inventions to Fund Research, Berkeley News (May 27, 2021), 
https://news.berkeley.edu/2021/05/27/uc-berkeley-will-auction-nfts-of-
nobel-prize-winning-inventions-to-fund-research/. 
71 Public Affairs, CRISPR portfolio now at 14 and counting, Berkley Research 
(Sep. 17, 2019), https://vcresearch.berkeley.edu/news/crispr-portfolio-now-
14-and-counting. 
72 Public Affairs, UC Now Holds Largest CRISPR-Cas9 Patent Portfolio, 
Berkeley News (Oct. 1, 2019), https://news.berkeley.edu/2019/10/01/uc-
now-holds-largest-crispr-cas9-patent-portfolio/. 
73 Licences, Caribou Biosciences, https://cariboubio.com/#licenses. 
74 Sanders, UC Rings, supra note 68.  
75 Information About Licensing CRISPR Systems, Including for Clinical Use, 
Broad Inst., available at https://www.broadinstitute.org/partnerships/office-
strategic-alliances-and-partnering/information-about-licensing-crispr-
genome-edi (last visited Sept. 10, 2021). 
76 Id. 
77 Information About Licensing CRISPR Systems, supra note 74. 
78 Id. 
79 Id. 





CRISPR-Cas9 license.80 If a primary licensee has plans to apply 
CRISPR-Cas9 to the same genes or diseases as its noncompetitor 
who submitted a development plan, then the non-competitor 
becomes a competitor and cannot obtain a CRISPR license.81  This 
model “enable[s] the primary licensee to devote sufficient investment 
to develop CRISPR-based genome editing technology to treat human 
diseases, while supporting broad development of medicines to reach 
many patients.”82  
Both UC Berkeley and Broad Institute’s licensing schemes risk 
excluding innovative companies from accessing CRISPR-Cas9 
technology. With an exclusive license over UC Berkeley’s vast 
CRISPR-Cas9 patent collection, Caribou has the discretion to choose 
which companies can sublicense and use UC Berkeley’s revolutionary 
technology. Broad Institute’s “inclusive innovation” licensing model, 
in practice, does not support the broad development of medicines. This 
model gives its primary licensee, Editas Medicine, run by “Feng Zhang 
of the Broad Institute of MIT and Harvard,”83 close to exclusive control 
over the CRISPR industry. UC Berkeley and Broad Institute’s 
licensing practices make it difficult for companies not affiliated with 
UC Berkeley or Broad Institute to enter the CRISPR market.  
III.  EXCLUSIVE LICENSING AND THE BIOTECHNOLOGY 
INDUSTRY 
The exclusive licensing schemes used by UC Berkeley and 
Broad Institute diminish the incentive for the academic community to 
research CRISPR-Cas9 application in gene-editing. Although 
academic and non-profit use of both institutes’ patents is allowed, the 
researchers and academics who use these patents “don’t have the right 
to market and sell products derived from their research.”84 An 
additional roadblock to CRISPR-Cas9 access is surrogate company 
approval requirements. The exclusive licenses granted to UC Berkeley 
and Broad Institute’s respective surrogate companies prohibit 
academic and nonprofit use of CRISPR-Cas9 for human therapeutics 
and treatment without the approval of the exclusive licensee.85 The 
surrogate model also disadvantages the patent owners, restricting UC 
      
80 Id. 
81 Id. 
82 Id.   
83 Sharon Begley, Exclusive CRISPR Licenses Slow Development of 
Therapies, Legal Experts Argue, STAT (Feb. 16, 2017), 
https://www.statnews.com/2017/02/16/crispr-exclusive-licenses/. 
84 Krieger, supra note 63.  
85 Contreras & Sherkow, supra note 64, at 698. 




Berkeley and Broad Institute’s ability to grant similar licenses to other 
companies without approval from their respective surrogate 
companies.86 
A. Congress’ Push to Make Federally Funded Research 
Accessible and the Exclusive Licensing That Followed 
Before 1980, open science prevailed in biotechnology, with 
researchers “more inclined to share scientific findings rather than 
shroud them in secrecy.”87 Some researchers from the 20th century 
biomedical community even viewed patenting biomedical discoveries 
as unethical.88 The social norms in the scientific community during this 
time were rooted in communalism which discouraged claiming 
property rights over inventions and keeping discoveries secret.89  
Unfortunately, in a bid to “encourage the development of 
commercializ[ing] products”, the United States Congress enacted the 
Bayh-Dole Act in 1980 along with several other pro-patent right acts.90 
These new laws allowed for the commercialization of publicly funded 
research, replacing the scientific community’s communalism norm 
with commercialization.91 The Bayh–Dole Act ushered in a new era of 
federally funded research, allowing inventions created from federally 
sponsored research to be owned by universities and institutions92 rather 
than being assigned to the federal government.93  
The act created a pathway to lucrative income by 
commercializing university-developed technology.94 This new 
revenue stream, which currently makes over $6 billion per year, led to 
a rise in licensing activity among academic institutions.95 By creating 
a uniform patent policy among federal agencies, the inventor 
protections created by the Bayh-Dole Act incentivized universities and 
      
86 Id. at 700. 
87 Yann Joly, Open Source Approaches in Biotechnology: Utopia Revisited, 
59 ME. L. REV. 385, 391 (2007).  
88 Id.  
89 Id. 
90 Joly, supra note 86.  
91 Id. 
92 Vladimir Drozdoff & Daryl Fairbairn, Licensing Biotech Intellectual 
Property in University–Industry Partnerships, COLD SPRING HARBOR 
PERSPECT MED. 1, 1 (2015), available at 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355252/. 
93 Bayh-Dole Act: Regulations Impacting Ownership of Patent Rights, 
University of Wisconsin-Madison Research, 
https://research.wisc.edu/bayhdole/ (last visited Sept. 23, 2021). 
94 Id. 
95 Drozdoff & Fairbairn, supra note 91 at 1.  





institutions to develop their research into lifesaving treatments.96 For 
example, the Bayh-Dole Act made it possible for the University of 
Michigan to create radioimmunotherapy, a treatment for a once 
incurable form of follicular non-Hodgkin’s lymphoma, out of 
Michigan’s pre-existing research.97 While the Bayh–Dole Act made 
federal-funded research more accessible to taxpayers98, the era 
following saw an increase in exclusive licensing schemes and 
surrogate companies.  
B. Exclusive Licensing Limits CRISPR-Cas9’s Potential 
The large patent portfolios of both UC Berkeley and Broad are 
at the root of the exclusive licensing problem. The overinclusive 
patents used by these institutions create a patent thicket inhibiting the 
further development of CRISPR-Cas9 technology and applications. A 
patent thicket occurs when multiple patents state broader claims than 
the actual invention discovered.99 When multiple patents cover the 
same area of technology, as is the reality of the CRISPR patent 
landscape, a thicket of existing patent rights develops.100  This thicket 
requires potential developers to obtain rights from each patent holder 
to minimize patent infringement liability.101 
The exclusive licenses used by UC Berkeley and Broad 
Institute further inhibit the full potential of CRISPR-Cas9 innovations, 
holding back genome research and development. An exclusive license 
is a contract that allows a licensee to exclusively exercise one or more 
of a patent owners’ rights for a specific period.102  License agreements 
are important to define the scope of rights being transferred and to lay 
out the compensation for those rights.103  License agreements also 
establish the risk each party takes on in carrying out the agreement.104  
      




99 Katherine M. Nolan-Stevaux, Open Source Biology: A Means to Address 




102 Drozdoff & Fairbairn, supra note 91, at 5. 
103 Id. at 2. 
104 Id.  




Licensing rights, such as, exclusive licenses, are typically limit 
by field of use restrictions.105 These restrictions inhibit a licensee’s 
ability to exploit all fields of use of one technology, safeguarding 
against one licensee controlling all preventive, diagnostic, and 
therapeutic use for diseases in humans, animals, and plants.106 
Although exclusive licenses are common in biotechnology, the 
exclusive licenses granted to Caribou and Editas by their respective 
founding institutions differ from the industry standard.  
Instead of granting the exclusive use of one gene or a section 
of a genome, the exclusive licenses UC Berkeley and Broad Institute 
use cover “every gene in the human body and every gene known to 
humankind.”107 One company is unlikely to research every aspect of 
the human genome, meaning certain gene therapies could go 
undeveloped or ignored.108 CRISPR-Cas9 patents and exclusive 
licenses covering all known genes in both plant and animal cells create 
an impossibility “for researchers to invent around”109 the patents 
owned by UC Berkeley and Broad Institute. 
Exclusive licenses covering the whole human genome restrict 
the use of CRISPR technology to certain profitable genes selected by 
surrogate companies and their sublicensees. This prevents CRISPR-
Cas9 from being used to develop less profitable gene therapies, 
hindering the technology’s full potential. Similar to for-profit 
companies, surrogate companies focus on profitability when deciding 
which genes to develop and which companies to grant sublicenses 
to.110 Currently, within human therapeutics, surrogate companies are 
focused on researching CRISPR-Cas9 effects on cancer, stem cells, 
sickle cell anemia, and cystic fibrosis.111 These diseases make up only 
a fraction of CRISPR-Cas9’s potential application in improving 
genetic diseases. This for-profit model inhibits the development of less 
profitable therapies, leaving the treatment of rare diseases or diseases 
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that affect disadvantaged communities unresearched or worse, 
undiscovered.112  
Gene-editing industry members, such as Editas’ co-founder 
George Church, believe exclusive licensees “have the potential to 
impede research into therapeutic genome editing.”113 The monopoly of 
therapeutic gene editing goes against the Patent and Trademark Law 
Amendments Act, a federal regulation created in 1980 to “promote the 
utilization of inventions arising from federally supported research or 
development.”114 Through this act, the public can petition for patents 
based on government-funded research to be licensed reasonably, 
allowing the patent to be utilized to its full potential.115 The issue of 
patent accessibility has reached the highest court in the land with the 
Supreme Court of the United States, emphasizing the purpose of 
patents, “which exist to promote creation.”116  
The tragedy of the anticommons, first used by Heller and 
Eisenberg in 1998, identifies the problem with over-inclusive 
licensing.117 The tragedy of the anticommons is the idea that many 
exclusive rights over a single resource will lead to the underutilization 
of the resource.118 This tragedy perfectly describes the accessibility 
issue created by UC Berkeley and Broad Institute’s CRISPR-Cas9 
licensing scheme. Because of the over-inclusive licensing of CRISPR-
Cas9 patents to surrogate companies, which in turn sublicense rights 
to others, the use of CRISPR-Cas9 is limited to the most profitable 
gene applications.  This over fragmentation of patent rights deters 
innovation and makes the application of less profitable genes unlikely 
to be explored. Abandoning the surrogate exclusive license model is 
realistic and can help UC Berkeley and Broad further develop the 
CRISPR gene-editing industry. Non-exclusive licensing schemes have 
been used by universities determined to promote innovation.119 Gene-
splicing patents issued to Stanford University in 1980 were never 
exclusively licensed but still managed to promote innovation, leading 
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to the creation and expansion of the biotechnology industry.120 
Similarly, CRISPR technology has the potential to further advance the 
biotechnology industry if the industry’s current exclusive licensing 
practices are altered.  
C. Alternatives to Exclusive Licenses. 
In 2006, a set of points were drafted to help research 
universities navigate the technology licensing of research tools. 121 
Over 100 universities worldwide endorsed the Nine Points to Consider 
in Licensing University Technology (the Nine Points), including the 
University of California (of which UC Berkeley is a campus)122, 
Harvard, and MIT.123 To encourage the further development of 
licensed technologies, Point Two of the Nine Points instructs 
universities to structure exclusive licenses that encourage the 
development and use of licensed research tool technology.124 CRISPR 
is generally thought of as a broadly applicable platform technology 
rather than an research tool that enables downstream research.125 
However, recently, researchers have begun exploring CRISPR as a 
research tool, expanding the gene editing technology past its current 
therapeutic purpose.126 With research tooling capabilities, UC 
Berkeley, and Broad Institute should consider the Nine Points when 
structuring CRISPR licenses.  
To implement Point Two, UC Berkeley and Broad Institute 
could issue narrowly drawn exclusive licenses to their surrogate 
companies, allowing for broader research and development of the 
human genome. 127 To be “mindful of the impact of granting overly 
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broad exclusive rights,”128 UC Berkeley and Broad Institute should 
limit the coverage of their exclusive licenses to select genes in the 
human genome, rather than allowing surrogate companies extensive 
control over all genes each institutions respective patents cover. This 
will allow the surrogate companies to continue their profit-focused 
research and development while encouraging a wider range of 
CRISPR-Cas9 gene therapies to be developed.129  
Alternatively, UC Berkeley and Broad Institute can meet Point 
Two without abandoning exclusive licensing by including 
performance milestones in their existing exclusive licenses.130 
Providing performance milestones will encourage surrogate 
companies to align with UC Berkeley and Broad Institute’s individual 
development goals while preserving the surrogate-university 
relationship. Milestones for CRISPR-Cas9 licenses could include 
requiring surrogates to apply CRISPR-Cas9 to specific genes or 
specific diseases within a reasonable timeline. 
UC Berkeley and Broad Institute could also include 
sublicensing requirements for surrogate companies to “address unmet 
market or public health needs.”131 Currently, Caribou and Editas have 
full discretion to sublicense CRISPR-Cas9 technology.132 
Implementing sublicensing requirements would allow Caribou and 
Editas to continue sublicensing while narrowing their discretion, 
requiring sublicenses to be given for genes or diseases the surrogates 
are not developing. Sublicensing requirements would not only preserve 
the surrogate exclusive license model but also allow wider CRISPR-
Cas9 application. 
Another way to broaden CRISPR-Cas9 development while 
continuing to grant exclusive licenses is by reserving the licensor’s 
right to license within the scope of the exclusive license.133 UC 
Berkeley and Broad Institute could use reserved rights to license 
CRISPR-Cas9 for use in areas that the surrogate companies are not 
interested in or do not have the resources to fully develop. Broad 
Institute’s current “inclusive innovation” model already allows for 
licenses to be given to third parties but only if the primary licensee is 
not interested in pursuing the same CRISPR applications.134 With the 
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reserved right, Broad Institute could license its CRISPR technology to 
a third party without presenting the third party’s development plan to 
Editas. This allows for broader application of CRISPR by multiple 
companies and encourages Editas to sublicense to more third parties 
because sublicensing gives them more control than licensing by Broad.   
A nonexclusive license could also be an alternative to UC 
Berkeley and Broad’s current overreaching exclusive licenses. 
Nonexclusive licenses generally allow the licensee to use patent rights 
without giving the licensee control over the enforcement or licensing 
of such rights.135 This licensing scheme allows the patent owner to 
grant the same rights to several parties.136 These licenses are most 
commonly seen used for platform technologies with wide applications 
in different fields of use.137 The application potential of CRISPR-Cas9 
can be compared to such platform technologies. However, with the 
additional liability risk that comes with developing genetic therapies, 
nonexclusive licenses are riskier than the exclusive licenses UC 
Berkeley and Broad Institute currently use.138 
IV.  OPEN-SOURCE IN THE BIOTECHNOLOGY INDUSTRY 
The biotechnology industry should model future licensing after 
the software industry’s open-source model to “enable researchers to 
improve the efficiency of research and decrease the transactions costs 
involved.”139 Open-source licensing is common in software code, 
which primarily relies on copyright protection.140 Although the 
biotechnology industry relies on patent protections, rather than 
copyright protections, open-source licensing is still a potential solution 
to allow for wide access to innovative biotechnologies. In software, the 
shift from “secret, copyrighted, and carefully litigated”141code to 
collaboration and free distribution of source code and data allowed the 
industry to accelerate development.142 An open-source approach could 
similarly benefit to the biotechnology industry, helping resolve the 
      
135 Drozdoff & Fairbairn, supra note 91, at 5. 
136 Id. 
137 Drozdoff & Fairbairn, supra note 91, at 5. 
138 See generally id. 
139 Nolan-Stevaux, supra note 98, at 279. 
140 Andrew C. Oliver, Open Source History Foretells the Future of Pharma 









patent thicket problem and anticommons dilemma previously 
discussed.143  
The most common open-source licenses are the General Public 
License (GPL) and the Berkeley Software Distribution License 
(BSD).144 GPLs are copyleft licenses that allow freedom to share and 
change free software.145 The less restrictive BSD allows free use of the 
BDS code if the required notices accompany the code.146 Open-source 
licenses can still provide a level of secrecy. Software creators looking 
to maintain secrecy can make BSD-licensed code private “since 
proprietary software that includes the BSD notice can be distributed in 
object code so that it may be maintained in secret.”147 Although not 
entirely convertible to the biotechnology industry, open-source license 
models like GPL and BSD can work as guides in creating open-source 
licenses that benefit biotechnology.  
There is a growing interest in the biotech industry to venture 
into the world of alternative business models.148 Open-source research 
and development is one alternative model that is gaining traction. 
Unlike the software industry, when used in the biotechnology field, 
open-source is a catch-all term to identify a scientific collaboration 
business model.149 Open source promotes sharing, rather than 
exclusivity, in the search for revolutionary, affordable medicine.150 
With more open-source access to research and development, less 
profitable disease therapies will have a better chance of gaining needed 
attention. Open-source practices could result in companies placing 
equal importance on medical advancement and profitability of new 
drugs therapies when deciding what information to release or which 
research to pursue.151  
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A. Examples of Open-Source Biotechnology Research and 
Development 
In 2015, Pfizer discovered that its rheumatoid arthritis drug, 
Enbrel, reduced the risk of Alzheimer’s by 64%.152 Rather than making 
their discovery accessible to outside companies or researchers, Pfizer 
buried the results.153 Pfizer claimed the results did not meet “rigorous 
scientific standards” and did not want others to be led astray.154 In 
reality, Pfizer took advantage of the accepted exclusivity plaguing the 
biotech industry, putting profit potential over development. Pfizer’s 
decision to put commercial incentives above valuable Alzheimer’s 
data, positive or negative, shows how the greater biomedical industry 
is disadvantaged by the rejection of open-source collaboration.155 
Pfizer, UC Berkeley, Broad Institute and the larger 
biotechnology community are making use of current biotechnology 
practices that, unfortunately, could have disastrous consequences for 
future innovation. The problem with UC Berkeley and Broad 
Institute’s exclusive licenses is the inability for research to be 
developed in less profitable gene therapies to begin with. Gene 
applications that could benefit less profitable diseases, such as tropical 
diseases that typically affect poor or developing countries, are not 
enticing to large companies looking for the next “blockbuster drug.”156 
This is because the commercial model Western companies operate 
under only works if a drug can be sold at a price and quantity that can 
cover the cost of R&D.157 This model fails with tropical diseases 
because, generally, few tropical disease patients can afford to pay a 
price that will recover a company’s high R&D costs.158 The 
disadvantage less profitable diseases have is evident by the lack of 
newly developed tropical disease drugs.159 It is estimated that only 
around 1% of newly developed drugs are for tropical diseases, such as 
African sleeping sickness, dengue fever, and leishmaniasis.160 
Fortunately, the biomedical industry may be pushed into 
accepting open-source research and development in the near future. 
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The recent global pandemic has assisted in accelerating open-source 
collaboration. Thanks to Chinese researchers openly publishing the 
COVID-19 genetic sequence, pharmaceutical companies and 
researchers were able to find existing drugs that have been repurposed 
to fight the virus and develop new vaccines quickly.161 The COVID-
19 pandemic is an incredible example of how open-source can benefit 
companies’ profits and public’s health. Advocates for open-source are 
hoping that the pandemic’s “open-source model can be replicated to 
address other challenges in biomedical research.” 162 
Even before the pandemic, some pharmaceutical companies 
were slowly moving toward open-source development. Offering a 
company’s intellectual property to the public risks losing out on profits 
and credit, but diseases that affect poor populations, like tropical 
diseases, do not provide large profits to begin with.163 Tropical diseases 
impact roughly one-sixths of the worlds population,164 yet 
pharmaceutical companies devote little time and resources toward 
cures because such diseases lack economic incentives.165 Tropical 
diseases are less commercially attractive because they take resources 
away from the research and development of “profitable” diseases that 
affect countries with rich populations willing and able to pay 
“blockbuster” drug prices.166  
The Tropical Disease Initiative (TDI) is a web-based open-
source drug development project tapping into the underdeveloped and 
less profitable tropical disease market.167 Collaboration between 
researchers from laboratories, universities, institutes, and corporations 
work together to explore under-researched tropical diseases benefiting 
populations traditionally ignored by the biomedical industry.168 
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Similarly, the Medicines for Malaria Venture (MMV), 
working toward new Malaria treatments, shipped hundreds of its 
Malaria Boxes to 200 researchers in 30 countries.169 The compounds 
in the Malaria Box that were used by one researcher “identified 
promising compounds that attacked the Plasmodium falciparum 
malaria parasite [leading] to further drug development work.”170 The 
same researcher even found compounds active against parasites 
unrelated to Malaria that could protect against a parasite that causes 
childhood blindness. 171 The Malaria Box and MMV’s other projects, 
the Pathogen Box and the Pandemic Response Box, show a realistic 
open-source research model.172 These boxes show the move from 
commercial drug research and development toward a collaborative 
model where intellectual property is shared instead of guarded.  
MMV also collaborated with GlaxoSmithKline and St. Jude 
Children’s Research Hospital to create a list of 20,000 potential 
antimalarials now logged in an open chemical database curated by the 
European Bioinformatics Institute.173 Open-Source Pharma 
Foundation, founded in 2018, is also an open-source “success story.” 
In 2019, the OSPF team took a generic diabetes drug into “Phase 2B 
clinical trials as a tuberculosis treatment.”174 Typically a new drug 
would cost $500 million to develop,175 but OSPF’s tuberculosis 
treatment required under $50,000 and took less than a year to develop, 
showing the cost and time efficiency of collaborative research.176 
B. The Biotechnology Industry’s Hesitation Toward Open-
Source 
Understanding why open-source was widely accepted in the 
software industry can help address the hesitation to adopt similar 
practices in other industries.177 In the early stages of the industry, 
software was the “Wild West of the legal world.”178 The unknown of 
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the industry allowed open-source to flourish, largely due to the 
inability of legislators, regulators, and policy-makers to comprehend 
the new software frontier.179  
Generally, the more reliant a field is on vested intellectual 
property interests, “the more resistant that field will be to the idea of 
open-source models.”180 Relying heavily on already existing and well-
regulated intellectual property protection, the biotechnology industry’s 
ability to explore new methods of sharing information and 
collaborating is limited. Open-source systems utilized by the software 
industry are not directly transferable to biotechnology.181 The notable 
differences between software and biotechnology create an exciting 
opportunity to customize open-source projects to fit specific 
biotechnology research.182  
Moving from tightly held secrets to open access is a radical 
idea for many companies. The Biological Innovation for Open Society 
(BiOS) initiative, created in 2005, is an open-source biological 
technologies project looking to promote open-source development in 
biotechnology, create new legal mechanisms to protect open-source 
developments, and provide intellectual property analysis to protect 
against patent liability.183 BiOS is working to accelerate companies’ 
open-source acceptance, with protections specific to biotechnology.184 
Projects like BiOS and other open-source research companies 
receiving public recognition provide promise for the biotechnology 
industry moving toward more open-source collaboration.  
Critics of open-source research fear that the lack of standards 
within an open-source process will deteriorate the quality of future 
scientific findings.185 This fear is unfounded given that open-source 
projects are not only constantly “peer-reviewed” but also continuously 
“peer improved”.186 With additional quality safeguards such as 
industry-developed Good Manufacturing Practices, Good Laboratory 
Practices, and Good Clinical Practices the fear of lackluster research 
and discovery becomes even less credible.187  
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C. Benefits to Open-Source in the Biotechnology Industry 
Benefits to an open-source model include the elimination of 
errors in research. Open access to research and findings “encourages 
an open, critical discussion in order to foster higher quality 
research.”188 Increased accessibility also allows for maximal early-
stage development.189 Receiving outside input during the early 
research phases, rather than after the initial discovery, will benefit the 
efficiency of the research and potentially cut down on research costs. 
190 Open databases and access to new research tools or promising 
therapeutics could allow neglected diseases to be properly studied.191 
Cutting back on cost will lead to better research for diseases and 
treatments affecting poor populations and developing nations.192  
Further economic benefits to implementing open-source in the 
biotechnology industry include reduced duplicate research.193 
Transparency cuts down excessive costs where research being perused 
by one has already been studied by another.194 Fear of profit loss in an 
open-source model is mitigated by making up profits that would have 
been generated through complementary goods and services.195 
Providing public access to technology and research companies can also 
boost their reputation as being innovative and socially conscious.196 
Interest from the public could also lead to volunteer labor, further 
cutting down the cost of research.197 Overall, open-source promises 
thorough review, revision, and modification by combining the know-
how from a wide pool of interested parties.198 
CONCLUSION 
In the past few years, CRISPR-Cas9 has developed a reputation as 
the future of gene editing, becoming a mainstream gene-editing 
technology. During this time, UC Berkeley and Broad Institute have 
established themselves as pioneers in the CRISPR-Cas9 industry. With 
court judgments and esteemed awards, UC Berkeley and Broad 
Institute have legitimate evidence to establish ownership of their 
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respective intellectual property, were they to be misused or stolen. The 
extensive legal battle between the two institutions found Broad 
Institute the “victor,” legitimizing its claim to its extensive CRISPR-
Cas9 patent portfolio.199 This past year, UC Berkeley has also 
solidified its place as a CRISPR pioneer, with the university’s 
biochemist, Jennifer Doudna, receiving the 2020 Nobel Prize in 
Chemistry200 for developing CRISPR-Cas9.201 This recognition makes 
both institutions’ ability to provide open-source access to select 
CRISPR-Cas9 gene applications possible and realistic, as it is evident 
that CRISPR-Cas9 therapy or treatment will have been a product of 
UC Berkeley or Broad Institute’s intellectual property.  
The CRISPR industry is still relatively new, being first discovered 
in 2012.202 Understandably, universities wish to keep intellectual 
property rights protected by licensing to surrogate companies. This 
surrogate licensing system gives universities more control over how 
their CRISPR-Cas9 technology is being used, while mitigating the risk 
associated with IP licensing. However, the current surrogate model 
used by the leaders of the CRISPR-Cas9 industry heavily restricts 
access to this revolutionary technology. Exclusive licenses are a 
common practice in biotechnology and should not be completely 
discarded from the universities’ intellectual property rights toolkit. 
However, while licenses are an important tool for protecting 
intellectual property, universities must change their current exclusive 
license system to allow more than just a handful of companies access 
to CRISPR-Cas9.  
While countless alternatives to exclusive licensing exist, open-
source collaboration provides numerous benefits and has already 
gained popularity as a useful tool in COVID19 research. Open-source 
should not eliminate licensing altogether. The open-source method is 
not a threat to the blockbuster drug development model, which is 
currently the standard in the biomedical industry.203 Companies can 
continue to use patents to protect the most commercially promising 
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intellectual property, while open-source collaboration can fill in the 
gaps of less profitable but still vital, research and development. 
UC Berkeley and Broad Institute’s extensive CRISPR-Cas9 patent 
portfolios could benefit from allowing selective open-source access. 
To suggest these institutions completely give up their intellectual 
property rights over CRISPR-Cas9 application would be naive. 
However, ignoring the move toward collaboration within the 
biotechnology field is also naive. UC Berkeley and Broad Institute 
should limit their exclusive licenses to select gene applications and 
allow open-source access to less profitable genes that otherwise may 
go ignored or unexplored otherwise. Broader access to CRISPR-Cas9 
intellectual property is in the best interest of the patent owner and the 
greater public because it encourages innovation, breeds healthy 
competition, and allows for CRISPR technology to be applied to a 
larger range of the human genome.   
